Real-world progression-free survival in first-line advanced non-small cell lung cancer treated with immunotherapy-based regimens using a US dataset
While results from clinical trials are important in determining the efficacy of treatment, restrictive eligibility criteria may limit generalizability to patient populations in the real-world setting. Real-world analyses can therefore identify subgroups of patients who may respond differently to spe...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-08-01
|
| Series: | Data in Brief |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2352340921004790 |
| _version_ | 1818691979814371328 |
|---|---|
| author | David Waterhouse Jenny Lam Keith A. Betts Lei Yin Sophie Gao Yong Yuan John Hartman Sumati Rao Solomon Lubinga David Stenehjem |
| author_facet | David Waterhouse Jenny Lam Keith A. Betts Lei Yin Sophie Gao Yong Yuan John Hartman Sumati Rao Solomon Lubinga David Stenehjem |
| author_sort | David Waterhouse |
| collection | DOAJ |
| description | While results from clinical trials are important in determining the efficacy of treatment, restrictive eligibility criteria may limit generalizability to patient populations in the real-world setting. Real-world analyses can therefore identify subgroups of patients who may respond differently to specific therapeutic regimens. This supplementary data is supportive to the research article entitled “Real-world outcomes of immunotherapy–based regimens in first-line advanced non-small cell lung cancer” [1]. Using electronic health records data from a large demographically and geographically diverse oncology database, we present real-world progression-free survival (rwPFS) outcomes for patients with advanced non-small cell lung cancer in the United States treated with either first-line immunotherapy as monotherapy or single-agent immunotherapy combined with chemotherapy. rwPFS was estimated for patients in each treatment group using Kaplan-Meier methods; analyses were conducted separately for patients with squamous and non-squamous histology and stratified by Eastern Cooperative Oncology Group performance status, tumor programmed death ligand-1 expression, and presence of brain metastases. |
| first_indexed | 2024-12-17T12:50:30Z |
| format | Article |
| id | doaj.art-a764dbdf6af741ba9f3f84cc2b459a8f |
| institution | Directory Open Access Journal |
| issn | 2352-3409 |
| language | English |
| last_indexed | 2024-12-17T12:50:30Z |
| publishDate | 2021-08-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Data in Brief |
| spelling | doaj.art-a764dbdf6af741ba9f3f84cc2b459a8f2022-12-21T21:47:37ZengElsevierData in Brief2352-34092021-08-0137107195Real-world progression-free survival in first-line advanced non-small cell lung cancer treated with immunotherapy-based regimens using a US datasetDavid Waterhouse0Jenny Lam1Keith A. Betts2Lei Yin3Sophie Gao4Yong Yuan5John Hartman6Sumati Rao7Solomon Lubinga8David Stenehjem9OHC Cincinnati, Cincinnati, OH, USA; Corresponding author.Bristol Myers Squibb, Lawrenceville, NJ, USAAnalysis Group, Los Angeles, CA, USAAnalysis Group, Los Angeles, CA, USAAnalysis Group, Los Angeles, CA, USABristol Myers Squibb, Lawrenceville, NJ, USABristol Myers Squibb, Lawrenceville, NJ, USABristol Myers Squibb, Lawrenceville, NJ, USABristol Myers Squibb, Lawrenceville, NJ, USAUniversity of Minnesota, Minneapolis, MN, USAWhile results from clinical trials are important in determining the efficacy of treatment, restrictive eligibility criteria may limit generalizability to patient populations in the real-world setting. Real-world analyses can therefore identify subgroups of patients who may respond differently to specific therapeutic regimens. This supplementary data is supportive to the research article entitled “Real-world outcomes of immunotherapy–based regimens in first-line advanced non-small cell lung cancer” [1]. Using electronic health records data from a large demographically and geographically diverse oncology database, we present real-world progression-free survival (rwPFS) outcomes for patients with advanced non-small cell lung cancer in the United States treated with either first-line immunotherapy as monotherapy or single-agent immunotherapy combined with chemotherapy. rwPFS was estimated for patients in each treatment group using Kaplan-Meier methods; analyses were conducted separately for patients with squamous and non-squamous histology and stratified by Eastern Cooperative Oncology Group performance status, tumor programmed death ligand-1 expression, and presence of brain metastases.http://www.sciencedirect.com/science/article/pii/S2352340921004790Non-small cell lung cancerReal-world outcomesImmunotherapyImmune checkpoint inhibitors |
| spellingShingle | David Waterhouse Jenny Lam Keith A. Betts Lei Yin Sophie Gao Yong Yuan John Hartman Sumati Rao Solomon Lubinga David Stenehjem Real-world progression-free survival in first-line advanced non-small cell lung cancer treated with immunotherapy-based regimens using a US dataset Data in Brief Non-small cell lung cancer Real-world outcomes Immunotherapy Immune checkpoint inhibitors |
| title | Real-world progression-free survival in first-line advanced non-small cell lung cancer treated with immunotherapy-based regimens using a US dataset |
| title_full | Real-world progression-free survival in first-line advanced non-small cell lung cancer treated with immunotherapy-based regimens using a US dataset |
| title_fullStr | Real-world progression-free survival in first-line advanced non-small cell lung cancer treated with immunotherapy-based regimens using a US dataset |
| title_full_unstemmed | Real-world progression-free survival in first-line advanced non-small cell lung cancer treated with immunotherapy-based regimens using a US dataset |
| title_short | Real-world progression-free survival in first-line advanced non-small cell lung cancer treated with immunotherapy-based regimens using a US dataset |
| title_sort | real world progression free survival in first line advanced non small cell lung cancer treated with immunotherapy based regimens using a us dataset |
| topic | Non-small cell lung cancer Real-world outcomes Immunotherapy Immune checkpoint inhibitors |
| url | http://www.sciencedirect.com/science/article/pii/S2352340921004790 |
| work_keys_str_mv | AT davidwaterhouse realworldprogressionfreesurvivalinfirstlineadvancednonsmallcelllungcancertreatedwithimmunotherapybasedregimensusingausdataset AT jennylam realworldprogressionfreesurvivalinfirstlineadvancednonsmallcelllungcancertreatedwithimmunotherapybasedregimensusingausdataset AT keithabetts realworldprogressionfreesurvivalinfirstlineadvancednonsmallcelllungcancertreatedwithimmunotherapybasedregimensusingausdataset AT leiyin realworldprogressionfreesurvivalinfirstlineadvancednonsmallcelllungcancertreatedwithimmunotherapybasedregimensusingausdataset AT sophiegao realworldprogressionfreesurvivalinfirstlineadvancednonsmallcelllungcancertreatedwithimmunotherapybasedregimensusingausdataset AT yongyuan realworldprogressionfreesurvivalinfirstlineadvancednonsmallcelllungcancertreatedwithimmunotherapybasedregimensusingausdataset AT johnhartman realworldprogressionfreesurvivalinfirstlineadvancednonsmallcelllungcancertreatedwithimmunotherapybasedregimensusingausdataset AT sumatirao realworldprogressionfreesurvivalinfirstlineadvancednonsmallcelllungcancertreatedwithimmunotherapybasedregimensusingausdataset AT solomonlubinga realworldprogressionfreesurvivalinfirstlineadvancednonsmallcelllungcancertreatedwithimmunotherapybasedregimensusingausdataset AT davidstenehjem realworldprogressionfreesurvivalinfirstlineadvancednonsmallcelllungcancertreatedwithimmunotherapybasedregimensusingausdataset |